Table 1.
Naive | Immunization route for omvPV | Difference*** | |||
Intranasal | Subcutaneous | ||||
Protection | Lung clearance | >6 days p.c. | ++++ (<1 day p.c.) | +++ (>1 day p.c.) | + |
Tracheal clearance | >6 days p.c. | ++++ (<1 day p.c.) | ++++ (<1 day p.c.) | 0 | |
Nasal clearance | >6 days p.c. | ++++ (<1 day p.c.) | ++ (>6 days p.c.) | +++ | |
Systemic immunity | Antibodies | ||||
Serum IgG | − | + +++ | + +++ | 0 | |
Serum IgG1 | − | ++++ | ++++ | + | |
Serum IgG2a | − | ++++ | +++ | + | |
Serum IgG2b | − | ++++ | +++ | + | |
Serum IgG3 | − | +++ | ++++ | − | |
Serum IgA | − | +++ | − | +++ | |
Serum IgG specificity* | − | OMV, Vag8, BrkA, Prn, U1, U3, U4, U6, LPS | OMV, Vag8, BrkA, Prn, GroEL, U1–2, U4–7, LPS | 0 | |
Plasma cells | |||||
IgG ASC Blood | − | + + | + + | 0 | |
IgG ASC Spleen | − | ++ | ++ | 0 | |
IgG ASC Lung | − | ++++ | ++ | ++ | |
Memory B-cells | |||||
IgG ASC Spleen | − | + + | + + | 0 | |
IgG ASC Lung | − | ++ | − | ++ | |
T-helper related cytokine responses | |||||
Spleen Th1 | − | + ++ | + ++ | 0 | |
Spleen Th2 | − | ++ | ++ | 0 | |
Spleen Th17 | − | ++++ | +++ | + | |
Mucosal immunity | Antibodies | ||||
Pulmonary IgA | − | ++++ | + | + ++ | |
Nasal IgA | − | ++++ | + | +++ | |
Pulmonary IgA specificity* | − | Vag8, LPS, U1–3 Vag8, | − | +++ | |
Nasal IgA specificity* | − | LPS | − | +++ | |
Plasma cells | |||||
IgA ASC Blood | − | + + | − | + + | |
IgA ASC Spleen | − | ++ | − | ++ | |
IgA ASC Lung | − | ++++ | − | ++++ | |
Memory B-cells | |||||
IgA ASC Lung | − | + ++ | − | + ++ | |
T-helper related cytokine responses | |||||
Pulmonary Th1 | − | + ++ | + | +++ | |
Pulmonary Th2 | − | + | − | + | |
Pulmonary Th17 | − | ++++ | + | ++++ |
*Based on combined results of MIA and Western blotting. **Scale ranges from – (absent) to ++++ (highly present). ***Difference between intranasal and subcutaneous omvPV immunization. + to ++++ is advantage intranasal, 0 is no difference, − is advantage subcutaneous.